Literature DB >> 19168329

Remission in schizophrenia: results from a 1-year follow-up observational study.

Antonio Ciudad1, Enric Alvarez, Julio Bobes, Luis San, Pepa Polavieja, Inmaculada Gilaberte.   

Abstract

OBJECTIVES: This study used the Remission in Schizophrenia Working Group operational-severity criteria to, a) provide descriptive data on prevalence and stability of symptomatic remission, b) attempt a criterion (concurrent) validation of this measure of remission, and c) explore correlates of remission stability.
METHODS: From an unselected sample of 1010 stable outpatients with schizophrenia (DSM-IV-TR), a subgroup of 452 (44.8%) in symptomatic remission was followed for 1 year. Of these, 376 were re-evaluated in a research diagnostic assessment. In addition to relevant sociodemographic and clinical data, measures included symptoms, depression, functioning, social cognition, attitudes towards medication, and quality of life. Estimates of point prevalence are provided. Correlates of remission were identified by logistic regression.
RESULTS: Symptomatic remission at baseline correlated with better premorbid adjustment, better social cognition, good treatment compliance, younger age, the absence of comorbid substance abuse, current or past participation in psychotherapy, and a lack of past participation in rehabilitation. After 1 year, 338 out of the 376 (89.9%) patients re-evaluated were found again in remission. In this assessment, better premorbid adjustment, good treatment compliance, and improvement of depressive symptoms and social cognition during follow-up again correlated with remission.
CONCLUSIONS: The results of this study suggest that symptomatic remission (as defined above) has considerable criterion validity and is a realistic goal in the treatment of schizophrenia. Attaining and sustaining remission may warrant better clinical and functional outcomes for patients.

Entities:  

Mesh:

Year:  2009        PMID: 19168329     DOI: 10.1016/j.schres.2008.12.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  Neurocognition: clinical and functional outcomes in schizophrenia.

Authors:  Martin Lepage; Michael Bodnar; Christopher R Bowie
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

2.  Symptomatic Remission Determines Functional Improvement and Quality of Life in Schizophrenia.

Authors:  Mehmet Hanifi Kokaçya; Osman Virit; Ümit Sertan Çöpoğlu; Haluk Savaş; Mustafa Ari; Bülent Bahçeci
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

3.  One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study.

Authors:  Konstantinos N Fountoulakis; Panagiotis Panagiotidis; Antonis T Theofilidis; Ioannis Nimatoudis
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-08-31       Impact factor: 2.582

4.  The SWITCH study: rationale and design of the trial.

Authors:  Stephan Heres; Diana Meliu Cirjaliu; Liana Dehelean; Valentin Petre Matei; Delia Marina Podea; Dorina Sima; Lynne Stecher; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-31       Impact factor: 5.270

5.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

Review 6.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

7.  Retrospective analysis of treatment effectiveness among patients in Mianyang Municipality enrolled in the national community management program for schizophrenia.

Authors:  Qingjin Li; Xuanyin Huang; Hong Wen; Xiaoqiong Liang; Lei Lei; Junlin Wu
Journal:  Shanghai Arch Psychiatry       Date:  2012-06

8.  Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Authors:  Virginia S Haynes; Baojin Zhu; Virginia L Stauffer; Bruce J Kinon; Michael D Stensland; Lei Xu; Haya Ascher-Svanum
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

9.  The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Authors:  William Montgomery; Li Liu; Michael D Stensland; Hai Bo Xue; Tamas Treuer; Haya Ascher-Svanum
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-14

Review 10.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Authors:  Cristiana Montemagni; Tiziana Frieri; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.